MiniMed宣布首次公开募股结束-动脉网

MiniMed announces closing of Initial Public Offering

PR Newswire 等信源发布 2026-03-10 04:59



可切换为仅中文







NORTHRIDGE, Calif.

北岭，加利福尼亚州

，

March 9, 2026

2026年3月9日

/PRNewswire/ -- MiniMed Group, Inc. (MiniMed; Nasdaq:

/PRNewswire/ -- 美敦力集团（MiniMed；纳斯达克：

MMED

) today announced the closing of its previously announced initial public offering (IPO) of 28,000,000 shares of its common stock at a price to the public of $20.00 per share. The shares began trading on the Nasdaq Global Select Market (Nasdaq) on March 6, 2026 under the symbol 'MMED.'

）今天宣布完成了此前宣布的首次公开募股（IPO），以每股20.00美元的价格发行了28,000,000股普通股。这些股票于2026年3月6日开始在纳斯达克全球精选市场（Nasdaq）交易，股票代码为“MMED”。

As of the closing of the IPO, Medtronic plc (Medtronic) owns approximately 90.03% of MiniMed common stock. Medtronic has previously stated that its preferred path to complete the separation is a split-off.

在首次公开募股（IPO）结束时，美敦力公司（Medtronic）持有MiniMed约90.03%的普通股。美敦力此前曾表示，其完成分拆的首选路径是分割出售。

After deducting underwriting discounts and commissions and estimated offering expenses payable by MiniMed, the net proceeds to MiniMed were approximately $538 million. MiniMed intends to use a portion of the net proceeds for general corporate purposes. The remainder have been used to repay intercompany debt owed to Medtronic..

扣除承销折扣、佣金以及MiniMed应支付的预估发行费用后，MiniMed的净收益约为5.38亿美元。MiniMed打算将部分净收益用于一般公司用途。剩余部分已用于偿还欠美敦力公司的内部债务。

Goldman Sachs & Co. LLC, BofA Securities, Citigroup and Morgan Stanley acted as the active bookrunners for the offering. Barclays, Deutsche Bank Securities, Mizuho, Wells Fargo Securities, Evercore ISI and Piper Sandler also acted as joint book running managers and BTIG and William Blair & Company, L.L.C.

高盛有限责任公司、美国银行证券、花旗集团和摩根士丹利担任此次发行的主动簿记管理人。巴克莱银行、德意志银行证券、瑞穗金融、富国银行证券、Evercore ISI 和 Piper Sandler 也担任联合簿记管理人，BTIG 和威廉布莱尔公司亦参与其中。

acted as co-managers. The offering was made only by means of a prospectus. Copies of the prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at +1-866-471-2526, by facsimile at +1-212-902-9316 or by email at .

担任联席经理。此次发行仅通过招股说明书进行。与首次公开募股（IPO）相关的招股说明书副本可从高盛公司有限责任公司获取，地址：纽约州纽约市西街200号，邮编10282，收件人：招股说明书部；电话：+1-866-471-2526；传真：+1-212-902-9316；或通过电子邮件索取。

[email protected]

电子邮件地址

; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, by email at

; 美银证券，NC1-022-02-25，北特里昂街201号，夏洛特，北卡罗来纳州，邮编28255-0001，招股说明书部收，电子邮件：

[email protected]

电子邮件地址

; Citigroup, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, telephone at +1-800-831-9146; and Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at

花旗集团，经由Broadridge金融服务公司，地址：纽约州埃奇伍德长岛大道1155号，邮编11717，电话：+1-800-831-9146；以及摩根士丹利公司，收件人：招股说明书部门，地址：纽约州纽约市瓦里克街180号2楼，邮编10014，或通过电子邮件发送至

[email protected]

电子邮件地址

。

A registration statement on Form S-1 relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

一份关于表格S-1的注册声明，涉及这些证券，已经提交给美国证券交易委员会（SEC）并已宣布生效。本新闻稿不构成出售要约或购买要约的邀请，也不得在任何州或司法管辖区进行这些证券的销售，如果在该州或司法管辖区的证券法规定下，此类要约、邀请或销售属于违法，则不得在注册或资格认证之前进行。

About MiniMed

关于MiniMed

MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service.

MiniMed是胰岛素输送领域的全球领导者，不断推进在80个国家支持糖尿病患者的治疗方案。我们全栈式的集成生态系统，包括胰岛素输送系统、连续血糖监测仪（CGM）、算法以及易于使用的应用程序体验，旨在无缝协作，并由周到细致的全方位服务提供支持。

For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes..

四十多年来，我们通过预测需求、减轻负担并帮助糖尿病患者更轻松地生活，开创了人们可以信赖的疗法。我们的使命是让糖尿病患者每一天都过得更好。

Cautions Regarding Forward-Looking Statements

关于前瞻性陈述的注意事项

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the offering and the use of proceeds therefrom. There are significant risks and uncertainties relating to the IPO.

本新闻稿包含1995年《私人证券诉讼改革法案》意义上的前瞻性陈述，这些陈述受风险和不确定性影响，包括与发行相关的风险以及发行所得款项的使用。首次公开募股（IPO）存在重大风险和不确定性。

Important factors that could cause actual results to differ materially from management's expectations include, without limitation: capital market risks and the impact of general economic or industry conditions. There can be no guarantees that MiniMed will achieve the anticipated benefits of the IPO.

可能导致实际结果与管理层预期存在重大差异的重要因素包括但不限于：资本市场风险以及整体经济或行业状况的影响。无法保证MiniMed能够实现IPO的预期收益。

The ability of MiniMed or Medtronic to achieve the anticipated benefits of the IPO may be materially affected by such factors as changes to the business, results of operations or financial condition of MiniMed or Medtronic, changes in the medical products industry, adverse market or macroeconomic conditions and other factors outside the control of MiniMed or Medtronic.

MiniMed或美敦力实现IPO预期效益的能力可能会受到多种因素的重大影响，例如MiniMed或美敦力的业务、经营结果或财务状况的变化、医疗产品行业的变化、不利的市场或宏观经济状况以及其他MiniMed或美敦力无法控制的因素。

For additional information about the factors that affect Medtronic's and MiniMed's businesses, please see their respective filings with the SEC. Each of Medtronic and MiniMed does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances..

有关影响美敦力和MiniMed业务的因素的更多信息，请参阅它们各自向美国证券交易委员会（SEC）提交的文件。美敦力和MiniMed均不承担更新其前瞻性声明或本新闻稿中包含的任何信息的责任，包括反映未来事件或情况。

MiniMed Contacts

MiniMed 联系人

Janet Cho

珍妮特·赵

Public Relations

公共关系

+1-818-403-7028

Ryan Weispfenning

瑞安·魏斯芬宁

Investor Relations

投资者关系